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Background: Anti-Galα1-3Gal antibodies (anti-αGal) represent a significant fraction of natural antibodies and 
were implicated in several disease states, yet their origin and physiological significance remain largely 
undisclosed. Methods: Under a prospective observational design, we estimated anti-αGal immunoglobulin G 
(IgG)/IgM and antipig hemolytic antibody (APA) levels in 133 patients starting dialysis therapy and again 
after a 1-year follow-up. We used baseline data to show correlations with demographic, nutritional, 
inflammatory, and anemia markers and analyzed their correlation with outcomes by using univariate and 
multivariate strategies of survival analysis. Results: Serum anti-αGal and APA levels showed wide baseline 
variability, but remained relatively stable in time. Both were measurable in dialysate of peritoneal dialysis 
(PD) patients, showing close correlation to serum levels. We observed no association between levels of anti-
αGal/APA and nutritional markers, but showed direct correlations of anti-αGal IgM (P = 0.005) and APA 
levels (P = 0.001) with tumor necrosis factor α (TNF-α) levels. High APA levels also were associated with 
severe anemia (P = 0.006). High baseline anti-αGal IgM (P = 0.03) and APA levels (P = 0.045) predicted 
later risk for enteric peritonitis in PD patients. Finally, univariate and multivariate analyses showed a 
consistent association between high baseline anti-αGal IgM (P = 0.014) and APA (P = 0.021) levels and 
global risk for mortality during follow-up. Conclusion: Anti-αGal IgM and APA levels at the start of dialysis 
therapy are significant predictors of later risk for mortality and, in PD patients, enteric peritonitis. Both 
correlate directly with TNF-α levels and, in the case of APA, severity of anemia in these patients. 
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THE TERMINATED TRISACCHARIDE structure Galα1-3Galβ1-4GlcNAc (αGal) epitope is 
widely present on the cell surface of most living creatures, from bacteria to mammals. Humans 
and higher primates constitute a notable exception to this rule, and in these species, a reciprocal 
evolutionary pattern has resulted in the presence of variable amounts of preformed circulating 
antibodies (anti-αGal) against this epitope.1 Anti-αGal represent a small, yet significant, fraction of 
natural antibodies.
2
 They are synthesized by approximately 1% of B lymphocytes,
3
 accounting for 
approximately 1% to 8% of circulating γ-globulins,4 and appear to be present consistently in 
human secretions.
5
 They are most notorious for representing a main barrier to xenotransplantation, 
yet their origin and physiological roles are still not clear despite ample investigation in this field.
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Current knowledge suggests that anti-αGals are synthesized continuously by peritoneal cavity–
derived B1 lymphocytes
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 as a response to lifetime contact between the organism and 
intestinal flora.
13
 They are able to bind to the surface of different Enterobacteriaceae, including 
Escherichia coli, Klebsiella species, and Serratia species, but it currently is unknown if they 
constitute a defense barrier against these bacteria.
13
 Anti-αGals may downregulate alternative 
complement pathway–dependent defense mechanisms, with a potential detrimental effect on the 
ability of the organism to combat infections by these microorganisms.
14
 This particularity may be 
aimed originally at limiting complement activation on the surface of senescent or abnormal 
erythrocytes, which anti-αGal contribute to clear from the circulation.15 Finally, anti-αGal also 
were implicated in the genesis of some autoimmune diseases.
16,
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Anti-αGal and antipig hemolytic antibodies (APAs; a relatively nonspecific estimator of the 
functional properties of anti-αGal) have been studied insufficiently in patients undergoing renal 
replacement therapy (RRT). Some years ago, we reported a preliminary cross-sectional survey of a 
small group of patients prevalent on RRT.
18
 We now report on a wider cohort of patients followed 
up prospectively after starting RRT. Our main points of interest are to disclose the basic 
demographic characteristics of anti-αGal and APA in patients starting RRT; assess the correlation 
between serum levels of these antibodies and the nutritional, inflammatory, and anemia status of 
these patients; compare the time course of anti-αGal levels in patients treated with peritoneal 
dialysis (PD) and hemodialysis; and analyze the potential correlation between anti-αGal levels at 
the start of RRT and clinical outcome (survival) of these patients. In PD patients, we also 
scrutinized for the presence of these antibodies in peritoneal fluid and searched for an association 
between baseline serum and dialysate anti-αGal levels and later risk for PD-related peritonitis. 
METHODS 
General Design 
Following a prospective observational design, we monitored serum anti-αGal and APA levels 
in 133 patients initiating RRT in our unit between August 1999 and December 2003. Follow-up 
was closed by August 2005. Patients were recruited consecutively. Exclusion criteria were 
unwillingness to cooperate in the study (1 patient), dialysis starting in an unstable clinical setting 
(34 patients) or after failure of a renal allograft (11 patients), and presumed early loss to follow-up. 
The latter group included 2 patients starting PD therapy and 66 patients starting hemodialysis 
therapy who were switched to other centers immediately after initiating RRT. Main reasons for 
these transfers were availability of dialysis therapy in a center closer to the patient’s residence area 
and/or incapacity of our center to treat more patients. These patients did not differ significantly 
from those continuing therapy in our center. Main characteristics of the study group are listed in 
Table 1. Patients beginning PD therapy were similar to those beginning hemodialysis therapy, 
except for a greater prevalence of diabetes in the former group (48.4% versus 23.1%; P = 0.005). 
No patient had a disseminated neoplasia or human immunodeficiency virus infection at the start of 
dialysis treatment. We estimated anti-αGal levels at baseline (median, 0 day; range, 0 to 33 days 
before the first dialysis session) and, in patients reaching 1 year in the same mode of RRT, again at 
the end of the first year. We also scrutinized at baseline selected clinical and biochemical markers, 
including nutritional (standard Subjective Global Assessment, albumin level, and prealbumin 
level), anemia (hemoglobin level and erythropoietin [EPO] dose), and inflammatory markers 
(high-sensitivity C-reactive protein [hs-CRP], interleukin 6 [IL-6], tumor necrosis factor α [TNF-
α], intercellular adhesion molecule [ICAM]), and residual renal function. 
Table 1. Study Population 
  
Age (y) 60 (7-87) 
Sex (men/women) 84/49 (63.2/36.8) 
Diabetes 54 (40.6) 
Charlson comorbidity score 6 (2-12) 
Malnutrition (Subjective Global Assessment) 13 (9.8) 
Chronic liver disease 10 (7.5) 
Chronic lung disease 12 (9.0) 
Steroid or immunosuppressive therapy 8 (6.0) 
Initial mode of RRT (PD/hemodialysis) 93/40 (69.9/30.1) 
  
 
NOTE. Values expressed as median (range) for numerical variables or number of cases (percent) for categorical variables. 
In a randomly selected group (n = 37) of patients starting PD therapy, we collected dialysate 
samples after a 12-hour dwell during their second week of PD therapy and, when possible, again at 
the end of the first year. We estimated anti-αGal and APA levels in these samples. 
Strategy of Analysis 
The study had a 4-fold objective: (1) to define basic demographic features of anti-αGal and 
APA in patients starting RRT and the time course of serum levels of these antibodies during the 
first year of dialysis therapy, with a specific interest in comparing effects of PD and hemodialysis; 
(2) to disclose potential correlations between baseline serum anti-αGal and APA levels and levels 
of selected inflammatory, nutritional, and anemia markers; (3) to analyze correlations of anti-αGal 
and APA levels with PD-related peritonitis, answering to a double-sense question: First, do serum 
or dialysate anti-αGal and/or APA levels predict the later incidence of peritonitis (overall) or 
enteric peritonitis during PD therapy? Second, do patients with peritonitis during their first year of 
PD therapy present a different time-course of anti-αGal or APA levels?; and (4) to assess the 
correlation between baseline serum levels of anti-αGal/APA and mortality during the course of 
RRT. 
Definition of Variables 
We used Charlson comorbidity score (which encompasses age and diabetes)
19
 to assess 
patients’ global baseline risk for mortality. Malnutrition was diagnosed according to standard 
Subjective Global Assessment, performed in all patients at the start of RRT; in practice, it was 
managed as a binary variable because of the relatively low prevalence of any degree of 
malnutrition, according to this method (Table 1). Anemia status was categorized conventionally as 
severe (hemoglobin ≤10 g/dL [≤100 g/L] and/or need for EPO therapy) or nonsevere (hemoglobin 
>10 g/dL [>100 g/L] and no EPO therapy) to facilitate data analysis. In patients treated with 
darbepoetin, a 1-μg:200 unit conversion factor to EPO was applied for analysis. PD-related 
peritonitis was defined according to standard criteria. We defined enteric peritonitis as episodes 
caused by Enterobacteriaceae, alone or in combination with Enterococcus species or intestinal 
anaerobic bacteria. 
  
Laboratory Methods 
Measurement of anti-αGal antibodies by enzyme-linked immunoassay.20 Microtiter plates were 
coated with 50 μg/well of αGal(1-3)βGal(1-4)GlcNAc linked to human serum albumin (5 μg/mL; 
Dextra Labs, Reading, UK) in 0.1 M of carbonate buffer, pH 9.6, overnight at 4°C. Coated plates 
were blocked with 200 μL/well of 0.5% Tween/phosphate-buffered saline (PBS; Sigma-Aldrich 
Lab, Steinheim, Germany) for 1 hour at room temperature. After washing, duplicate dilutions of 
serum prepared with 0.5% Tween/PBS, ranging from 1:2.5 to 1:320 or 1:10 to 1:1280, were 
pipetted (50 μL/well) to the antigen-coated wells and into uncoated blank wells serving as controls 
for nonspecific antibody binding. After incubation for 1 hour at room temperature, plates were 
washed 6 times with 0.1% Tween/PBS and incubated with horseradish peroxidase–labeled goat 
F(ab′)2 antihuman immunoglobulin G (IgG; γ chain specific) or IgM (μ chain specific; Sigma, St 
Louis, MO) at 1:200 in 0.5% Tween/PBS for 1 hour at room temperature. After 6 washes with 
0.1% Tween/PBS, the plate was developed with a solution of orthophenylene diamine (Sigma), 
prepared according to the manufacturer’s instructions, and quenched with 1 m of H2SO4 before 
reading absorbance at 492 nm. Anti-αGal IgG or IgM levels in different assays were normalized 
by comparison to a pool of human sera provided by the local blood bank, set at 1,000, which was 
included in all assays. 
APA measurement.
20
  Clotted blood samples were spun for 5 minutes at 3,000 rpm at 4°C. Sera 
then were collected, transferred into Eppendorf tubes, and heat inactivated at 56°C for 30 minutes. 
Subsequently, each serum was diluted serially in a 96-well plate with complement fixation diluent 
(ICN, Costa Mesa, CA) from 1:2.5 to 1:1280. After the addition of rabbit complement (Serotec, 
Oxford, UK) and 1% porcine red blood cells, plates were placed in an orbital incubator at 37°C for 
1 hour and centrifuged for 10 minutes. Next, 100 μL of supernatant from each well was transferred 
into reading plates. The reading was performed using a Labsystems Multiskan Plus (Labsystems, 
Helsinki, Finland) at a wavelength of 420 nm. Mean absorbance of the 2 replicates was calculated 
for each dilution and expressed in area under the curve units, considering the number of area under 
the curve units of the pool of human control serum as equal to 1,000. 
 
The APA assay provides information about functional properties of antibodies, detecting rabbit 
complement-fixing antibodies that bind to porcine red blood cells. In normal conditions, anti-
αGals are the main, but not only, natural antibodies responsible for the result of this assay. 
Other Laboratory Methods 
Coefficients of variation (SD/mean) of main laboratory variable estimations were 0.83 (anti-
αGal IgG), 0.84 (anti-αGal IgM), and 0.87 (APA). PD dialysate samples underwent concentration 
(×5) using Millipore Amicon Ultra-4 centrifugal filter devices (PL-10, 10,000 NMWL; Millipore, 
Billerica, MA) before estimation of anti-αGal and APA levels. Hemoglobin, albumin, prealbumin, 
urea, and creatinine levels were estimated by using standard autoanalyzers. Residual renal function 
was calculated after 24-hour urine collections as the mean of urea and creatinine clearances. hs-
CRP level was estimated by means of immunoturbidimetry (Roche Diagnostics, Mannheim, 
Germany). Serum IL-6, TNF-α, and ICAM levels were estimated by means of enzyme-linked 
immunosorbent assay (R&D Systems, Minneapolis, MN). 
Statistical Analysis 
Numerical variables are presented as median and range. Statistical analysis was carried out 
using univariate nonparametric tests: Mann-Whitney, Kruskal-Wallis (unpaired data), and 
Wilcoxon (paired data) tests for comparison of numerical variables and chi-square analysis for 
comparison of categorical variables. Univariate correlations between numerical variables were 
assessed from Spearman correlation coefficient. Bland-Altman plots were used to represent 
graphically the concordance between baseline and 1-year anti-αGal levels. Multivariate correlates 
of anti-αGal and APA levels were explored according to multiple regression and logistic 
regression (anemia) analysis. Analysis of mortality or survival to the first episode of peritonitis 
(overall or enteric) was carried out by using the Kaplan-Meier method (comparisons by means of 
log-rank test; univariate) and Cox model (multivariate). Patients were censored at renal 
transplantation or loss to follow-up and, in the case of peritonitis risk analysis, also in case of 
death or switch to hemodialysis therapy. SPSS 12.0 software (SPSS Inc, Chicago, IL) was used to 
produce statistical analysis. 
RESULTS 
Baseline 
Baseline serum anti-αGal and APA levels showed wide variability (Table 2), but were 
interrelated significantly: anti-αGal IgG-anti-αGal IgM (r = 0.44; P < 0.001), anti-αGal IgG-APA 
(r = 0.40; P = 0.001), and anti-αGal IgM-APA (r = 0.70; P < 0.001). 
Table 2. Main Baseline Laboratory Variables 
  
Anti-αGal IgG* 359 (13-1,898) 
Anti-αGal IgM* 331 (21-2,463) 
Anti-APA* 712 (27-4,141) 
Albumin (g/dL) 3.6 (2.1-4.6) 
Prealbumin (mg/dL) 31 (9-61) 
Hemoglobin (g/dL) 10.1 (6.4-15.0) 
EPO dose (U/wk)†† 4,000 (0-12,000) 
hs-CRP (mg/L) 7 (1.2-85) 
IL-6 (pg/mL) 5.0 (0.0-101.0) 
TNF-α (pg/mL) 6.0 (0.1-15.7) 
ICAM (ng/mL) 269 (21-882) 
Mean renal clearance (mL/min) 6.1 (0-12.6) 
  
 
NOTE. Values expressed as median (range). To convert albumin and hemoglobin in g/dL to g/L, multiply by 10; renal 
clearance in mL/min to mL/s, multiply by 0.01667.  
* Dimensionless.  
† In patients treated with darbepoetin, 1 μg:200 units equivalence was applied.  
There were trends to greater anti-αGal IgM (median, 375 versus 282; P = 0.03, Mann-
Whitney) and APA levels (median, 841 versus 661; P = 0.09) in women than men (anti-αGal IgG, 
not significant [NS]). We also observed a weak trend to an inverse correlation between age and 
APA level (r = −0.18; P = 0.04). Conversely, we did not detect a correlation between any of the 
following clinical markers and baseline serum anti-αGal or APA levels: underlying disease, 
Charlson score, diabetes, mode of dialysis (intention to treat), malnutrition by means of Subjective 
Global Assessment, cardiovascular comorbidity, chronic liver or lung disease, or current treatment 
with steroids or immunosuppressants at the start of RRT, either on univariate or multivariate 
analysis. 
 
Baseline values for the selected laboratory nutritional, anemia, and inflammatory markers 
scrutinized are listed in Table 2. 
  
Time Course of Anti-αGal and APA Levels 
Eighty-one patients completed a minimum follow-up of 1 year and had a second estimation of 
anti-αGal and APA levels at this time. Reasons for dropping out during the first year included 
death (n = 16), renal transplantation (n = 20), change in dialysis mode (n = 6), and loss to follow-
up or failure to obtain a second estimation of antibodies (n = 10). 
 
Median values (dimensionless) at the end of the first year were 372 (range, 8 to 2,237) for anti-
αGal IgG, 277 (range, 20 to 3,228) for anti-αGal IgM, and 775 (range, 59 to 6,976) for APA. 
Again, both variables were interrelated significantly: anti-αGal IgG–anti-αGal IgM (r = 0.46; P < 
0.001), anti-αGal IgG-APA (r = 0.39; P = 0.002), and anti-αGal IgM-APA (r = 0.81; P < 0.001). 
 
APA levels tended to increase from baseline to the end of the first year (median, 551 to 775; P 
= 0.04), whereas anti-αGal IgG and IgM levels remained essentially stable. There were strong 
correlations between baseline and 1-year levels of anti-αGal IgG (r = 0.86; P < 0.001), anti-αGal 
IgM (r = 0.81; P < 0.001), and APA (r = 0.64; P < 0.001). Bland-Altman plots showed a high 
degree of concordance between baseline and 1-year anti-αGal levels, although this concordance 
was lower in patients with highest serum levels (Fig 1). 
 
 
 
Fig 1. Bland-Altman plots of concordance between baseline and 1-year serum (A) anti-αGal IgG, (B) anti-αGal IgM, and 
(C) APA levels. 
  
Whereas anti-αGal and APA levels remained essentially stable in elderly patients, there were 
trends to an increase in APA (P = 0.009) and anti-αGal IgM (P = 0.09) levels from baseline to the 
end of the first year in younger patients (<60 years; anti-αGal IgG, NS). Neither PD nor 
hemodialysis patients presented a significant change in anti-αGal or APA levels, but both anti-
αGal IgM (median, 260 versus 463 units; P = 0.03) and APA levels (632 versus 990 units; P = 
0.09) tended to be lower in PD patients than hemodialysis patients at the end of the first year (anti-
αGal IgG, NS). 
Anti-αGal and APA Levels in Dialysate (PD Patients) 
Baseline median dialysate levels were 37 (range, 0 to 1,010; anti-αGal IgG), 33 (range, 0 to 
317; anti-αGal IgM), and 84 (range, 11 to 344; APA). These 3 variables were interrelated in a 
similar way to serum levels: anti-αGal IgG–anti-αGal IgM (r = 0.36; P = 0.07), anti-αGal IgG-
APA (r = 0.25; P = 0.20), and anti-αGal IgM-APA (r = 0.44; P = 0.03). Dialysate levels also 
correlated significantly with simultaneous serum levels: anti-αGal IgG, r = 0.53 (P = 0.008); anti-
αGal IgM, r = 0.46 (P = 0.03); and APA, r = 0.38 (P = 0.05). 
 
We obtained new dialysate samples at the end of the first year for 20 patients, and median anti-
αGal levels were 30 (range, 0 to 868; anti-αGal IgG), 32 (range, 0 to 136; anti-αGal IgM), and 74 
(range, 15 to 285; APA; NS versus baseline). 
Correlation With Other Laboratory Markers 
Baseline correlations of anti-αGal and APA levels with the selected nutritional, inflammatory, 
and anemia markers are listed in Table 3. There was a trend to a direct correlation between anti-
αGal IgM and APA and simultaneous TNF-α levels. Conversely, we observed no association 
between serum natural antibody or APA levels and those of hs-CRP, IL-6, or ICAM. 
Table 3. Correlations Between Anti-αGal and APA Levels and Laboratory Markers 
 
Anti-αGal IgG Anti-αGal IgM APA 
    
Albumin −0.02 (0.81) −0.17 (0.05) −0.06 (0.48) 
Prealbumin −0.09 (0.37) 0.004 (0.96) −0.02 (0.83) 
hs-CRP −0.08 (0.47) −0.16 (0.10) −0.01 (0.96) 
IL-6 0.06 (0.51) −0.06 (0.59) 0.09 (0.32) 
TNF-α 0.14 (0.14) 0.25 (0.005) 0.30 (0.001) 
ICAM 0.04 (0.66) −0.06 (0.56) −0.05 (0.61) 
Hemoglobin −0.12 (0.17) −0.07 (0.41) −0.17 (0.05) 
EPO dose −0.15 (0.09) −0.08 (0.40) 0.18 (0.04) 
Mean renal clearance 0.02 (0.84) −0.14 (0.16) −0.14 (0.18) 
    
 
NOTE. Values expressed as Spearman correlation coefficient ( P). 
  
APA levels (but not anti-αGal IgG or IgM levels) correlated directly with severity of anemia 
(Table 3). Patients with nonsevere anemia had significantly lower baseline serum APA levels than 
patients with severe anemia (Fig 2; anti-αGal IgM and IgG, NS). Logistic regression analysis 
identified residual renal function (odds ratio, 0.80 per mL/min; 95% confidence interval [CI], 0.67 
to 0.95; P = 0.013) and the higher (odds ratio, 4.78; 95% CI, 1.57 to 14.56; P = 0.006), but not the 
median (odds ratio, 1.67; 95% CI, 0.56 to 4.96; P = 0.36 versus lower), tertiles of baseline serum 
APA levels as the main independent predictors of severe anemia at the start of RRT (Charlson 
score, malnutrition, and other laboratory markers, NS). 
 
 
 
Fig 2. Baseline serum (A) anti-αGal IgM and (B) APA levels according to severity of anemia. Comparisons using Mann-
Whitney test. To convert hemoglobin in g/dL to g/L, multiply by 10. 
Anti-αGal, APA, and Peritonitis in PD Patients 
During the study period, we recorded 74 episodes of infectious peritonitis (1 episode every 
31.4 patient-months). The etiologic spectrum was similar to that of other studies, with a 
predominance of gram-positive bacteria (n = 41; 55.4%). Only 51 patients (54.8%) were free of 
peritonitis at the end of follow-up, whereas 27 patients (29.0%) experienced at least 1 episode of 
peritonitis, but no enteric peritonitis. Finally, we observed 18 instances of enteric peritonitis (8 
episodes, polymicrobial) in 15 patients (16.1%). The first episode of enteric peritonitis occurred a 
median of 5 months after the start of PD therapy (range, 1 to 29 months); in 11 cases (73.3%), it 
occurred during the first year of PD therapy. No patient died, but 3 patients were switched to 
hemodialysis therapy as a direct consequence of enteric peritonitis. 
 
Table 4 lists baseline serum and dialysate anti-αGal and APA levels in PD patients without 
peritonitis, with nonenteric peritonitis only, and with enteric peritonitis during follow-up. We 
observed no association between anti-αGal or APA levels and later risk for nonenteric peritonitis, 
but greater baseline serum and dialysate anti-αGal IgM and APA levels were evident in patients 
developing enteric peritonitis during follow-up. Kaplan-Meier analysis confirmed these trends 
(dialysate anti-αGal and APA levels not scrutinized because of insufficient statistical power). 
Patients at the highest tertile of baseline anti-αGal IgM and APA (but not anti-αGal IgG) levels 
showed a significant risk for enteric peritonitis during their first year of PD therapy (Fig 3). 
Multivariate analysis (Cox model) identified baseline serum anti-αGal IgM (hazard ratio, 2.1; 95% 
CI, 1.1 to 4.3; P = 0.03) or, to a lesser extent, baseline serum APA level (hazard ratio, 1.8; 95% 
CI, 0.95 to 3.5; P = 0.07) as the only independent predictors of risk for enteric peritonitis during 
follow-up (age as the only control variable included in the model; anti-αGal IgG and other clinical 
or laboratory variables, NS).  
Table 4. Baseline Anti-αGal and APA Levels and Risk for Peritonitis in PD Patients 
 
No Peritonitis Nonenteric Peritonitis Enteric Peritonitis 
    
Anti-αGal IgG serum 361 (13-1,898) 315 (13-1,367) 314 (68-1,367) 
Anti-αGal IgM serum 312 (40-2,463) 319 (21-1,227) 612 (57-1,247)*†† 
APA serum 639 (74-3,839) 764 (67-4,141) 1,169 (92-1,929)* 
Anti-αGal IgG dialysate 30 (0-238) 55 (0-1,000) 70 (18-745) 
Anti-αGal IgM dialysate 34 (2-317) 31 (0-294) 89 (29-294)*†† 
APA dialysate 81 (20-208) 99 (11-344) 178 (11-344)‡‡ 
    
 
NOTE. Values expressed as median (range; dimensionless). Comparisons by means of Mann-Whitney test.  
* P < 0.05 versus no peritonitis.  
† P < 0.05 versus nonenteric peritonitis.  
‡ P = 0.06 versus no peritonitis. Other differences NS.  
 
 
 
Fig 3. Survival to the first episode of enteric peritonitis according to tertile of baseline (A) anti-αGal IgG, (B) anti-αGal 
IgM, and (C) APA levels. Comparisons using log-rank test. 
 
  
We did not detect a different time course of serum or dialysate anti-αGal or APA levels in 
patients with nonenteric or enteric peritonitis during their first year of PD therapy. 
Anti-αGal, APA, and Survival on Dialysis Therapy 
Table 5 lists hemodialysis and PD patient status at the end of follow-up. Univariate Kaplan-
Meier analysis showed trends to lower survival in patients with the higher tertiles of APA (P = 
0.002 versus lower tertile) and anti-αGal IgM levels (P = 0.08 versus lower tertile), but not anti-
αGal IgG levels (Fig 4). Multivariate analysis confirmed these trends, indicating that both baseline 
serum APA and anti-αGal IgM levels were independent predictors of risk for mortality (Table 6). 
This association persisted after controlling for clinical, inflammatory, and nutritional markers. 
Lack of statistical power hampered in-depth exploration of whether this association could be 
restricted to specific causes of death, but Kaplan-Meier analysis suggested similar trends for 
cardiovascular and noncardiovascular mortality. 
Table 5. Patient Status at the End of Follow-Up 
 
PD (n = 93) Hemodialysis (n = 40) 
   
Follow-up (mo) 25 (2-60) 32 (3-72) 
Still on same mode of dialysis 25 (26.9) 15 (35.0) 
Switch to another modality 8 (8.6) 1 (2.5) 
Renal transplant 26 (28.0) 11 (27.5) 
Loss to follow-up 3 (3.2) 2 (5.0) 
Death 31 (33.3) 11 (27.5) 
 Cardiovascular 14 (45.2) 6 (54.5) 
 Infectious 3 (9.7) 0 (0) 
 Dementia/failure to thrive 4 (12.9) 2 (18.2) 
 Other/multifactorial 7 (22.6) 2 (18.2) 
 Uncertain 2 (6.5) 1 (9.1) 
   
 
NOTE. Values expressed as median (range) for follow-up or number of cases (percent) for all other. 
  
 
 
 
Fig 4. Patient survival according to tertile of baseline (A) anti-αGal IgG, (B) anti-αGal IgM, and (C) APA levels. 
Comparisons using log-rank test. 
Table 6. Patient Survival According to Baseline Serum Anti-αGal and APA Levels, Multivariate 
 
Anti-αGal IgG Model Chi-Square 
= 39.0; P < 0.0005 
Anti-αGal IgM Model Chi-Square 
= 41.4; P < 0.0005 
APA Model Chi-Square = 
43.7; P < 0.0005 
    
Charlson score (per 
point) 
1.41 (1.15-1.73) P < 0.001 1.35 (1.15-1.59) P < 0.001 1.41 (1.17-1.70) P < 0.001 
IL-6 (per pg/mL) 1.03 (1.01-1.05) P = 0.008 1.04 (1.02-1.06) P < 0.001 1.03 (1.01-1.05) P = 0.002 
Albumin (per g/dL) 0.93 (0.87-0.98) P = 0.023 Out of model 0.95 (0.89-1.00) P = 0.05 
Anti-αGal/APA (per 
tertile) 
1.15 (0.75-1.77) P = 0.53 1.71 (1.11-2.71) P = 0.014 1.67 (1.06-2.63) P = 0.021 
    
 
NOTE. Values expressed as hazard ratio (95% CI) P. Cox model. Best model with each anti-αGal/APA marker. Other 
variables not significant (sex, mode of dialysis, hemoglobin level, EPO dose, TNF-α level, ICAM level, mean renal 
clearance) or not fitting best model (hs-CRP level, prealbumin level, malnutrition by means of Subjective Global 
Assessment). 
 
  
DISCUSSION 
Our results confirm the notion that serum anti-αGal and APA levels show wide variability 
between patients starting RRT, as previously shown in healthy people
21
 and individuals awaiting 
renal transplantation.
22
 Moreover, these levels appear to be relatively stable in time, shown by the 
strong correlation and high degree of concordance (Fig 1) between baseline and 1-year anti-αGal 
levels. Only APA levels increased slightly after 1 year of dialysis therapy, at the expense of 
younger patients. Conversely, the only apparent, yet weak, demographic correlates of anti-αGal 
levels in our study were sex and age. Anti-αGal IgM levels previously were reported to be greater 
in women among healthy individuals,
21
 whereas older patients previously were claimed to present 
greater serum levels of low-affinity anti-αGal than younger patients.23 As a final comment to the 
demographic analysis in our study, we emphasize that sample size limits the significance of 
negative data in specific subsets (eg, patients on immunosuppressive therapy). 
 
Recurrent lavage of B1 cells, which may be located preferentially in the peritoneal cavity,
7,
 
8,
 
9,
 
10,
 
11,
 
12
 could have a potential impact on the time course of serum anti-αGal levels during PD 
therapy. However, we did not observe a significant difference between the time course of serum 
anti-αGal or APA levels in patients undergoing PD or hemodialysis. A previous study of humans24 
showed that long-term PD treatment results in a 50% decrease in numbers of B lymphocytes 
(including B1) in the peritoneal cavity, without an apparent impact on total serum or salivary 
immunoglobulin levels (anti-αGal levels were not specifically scrutinized). In our study, both anti-
αGal IgM and APA levels tended to be lower in PD patients after 1 year of RRT, but this may be 
the consequence in part of selection bias because PD patients with greatest levels of these 2 
markers were more likely to abandon PD therapy during the first year because of their increased 
risk for enteric peritonitis. 
 
Our study indicates that nutritional status of uremic patients does not influence significantly 
serum anti-αGal or APA levels. Neither of these antibodies appears to correlate clearly with well-
known markers of inflammation, although we were able to detect a moderate direct correlation 
between APA and anti-αGal IgM levels on one side and TNF-α levels on the other. It is widely 
accepted, but unproved, that continuous contact between the human organism and gram-negative 
resident intestinal bacteria triggers anti-αGal synthesis.13, 20 However, it presently is unclear 
whether recurrent intestinal transmigration of bacteria may contribute to the inflammatory status of 
some dialysis patients or, alternatively, inflammatory states may have a detrimental effect on the 
competence of the intestinal barrier in a way similar to the case of critical patients,
25
 thus favoring 
the interaction between the immune system and intestinal bacteria. Results of our study do not 
contribute to clarify this point. 
 
Our study shows a significant correlation between APA (but, interestingly, not anti-αGal IgM 
or IgG) levels (Fig 2) and severity of anemia in patients starting RRT, indicating that the 
hemolytic activity of these antibodies may be clinically significant in these patients. Anti-αGals 
were implicated in the clearance of senescent or abnormal erythrocytes,
15
 but discordant 
correlations between anti-αGal IgM and APA levels (which usually correlate closely) on one side 
and severity of anemia on the other suggest that a non–anti-αGal fraction of APA-related natural 
antibodies may be involved in the genesis of anemia of our patients. Our laboratory recently 
showed that these non–anti-αGal APA–related antibodies are polyreactive and able to recognize 
both pig and human cells (R.M., N.D.; unpublished data). However, similar to the case of 
inflammatory markers, evidence provided by our study is far from conclusive, and additional 
studies are necessary to confirm and interpret these correlations. 
 
Baseline anti-αGal IgM and APA levels were significant predictors of risk for enteric 
peritonitis during PD therapy. This finding is not unexpected given the presumed origin of anti-
αGal. Our data mainly are consistent with the hypothesis that high serum and dialysate anti-αGal 
IgM and APA levels signal patients with a disabled intestinal barrier, greater risk for bacterial 
transmigration, and, consequently, enteric peritonitis during PD therapy. However, we cannot rule 
out a pathogenic role of anti-αGal in the progression from transient contamination to overt 
peritoneal infection because these antibodies were reported to be detrimental to complement-
mediated clearance of intestinal bacteria.
14
  
A remarkable finding of our study is the consistent ability of serum anti-αGal IgM and APA 
levels to predict mortality in patients starting RRT. This effect persisted after controlling for a 
comprehensive (age, diabetes, comorbidity) prognostic marker, such as Charlson score and IL-6 
and albumin levels (Table 6). Our data also indicate similar risk for cardiovascular and 
noncardiovascular mortality, although cardiovascular disease had either a direct or permissive role 
in the majority of deaths. We do not have a clear explanation for these findings. High anti-αGal 
and APA levels could be simple bystanders in poor-quality patients, but if this is the case, a 
baseline association of anti-αGal/APA levels with Charlson score and markers of malnutrition and 
inflammation should be expected. The moderate correlations found with TNF-α levels and anemia 
(Table 3) could be clues to this type of relationship, but anti-αGal and APA could have a potential 
pathogenic role in these associations. Enteric peritonitis is another putative pathway to mortality in 
patients with high baseline serum anti-αGal IgM and APA levels. It is true that no patient died as a 
direct consequence of these infections; however, their debilitating effects could contribute to later 
mortality in some cases. However, the possibility that high anti-αGal and APA levels may be 
directly pathogenic cannot be ruled out. The physiopathologic characteristics of these antibodies 
remain unknown for the most part, but their potential roles in inhibition of complement-mediated 
clearance of intestinal bacteria,
14
 anemia,
15
 and autoimmune disease
16,
 
17
 suggest they potentially 
may be pathogenic, at least under certain concentrations or conditions. The last hypothesis clearly 
is speculative, but in the last years, there has been renewed interest in the potential role of natural 
antibodies in the pathogenesis of several diseases, including disorders of early defense against 
microbial disease,
26
 autoimmunity, and atherosclerosis.
27
 
 
In conclusion, serum anti-αGal IgM and APA levels at the start of RRT are associated 
significantly with risk for mortality and, in PD patients, enteric peritonitis during follow-up. Also, 
these antibodies correlate directly with serum TNF-α levels and, in the case of APA, severity of 
anemia in these patients. Additional studies are warranted to clarify the significance of these 
findings. 
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